Survival Time in Hematologic Malignancies Obeys Newcomb-Benford Law

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Mayo Clinic proceedings 2022-02, Vol.97 (2), p.419-420
Hauptverfasser:	Al-Juhaishi, Taha, Al-Kindi, Sadeer G
Format:	Artikel
Sprache:	eng
Schlagworte:	Databases, Factual Hematologic Neoplasms - mortality Hematologic Neoplasms - therapy Humans Models, Theoretical Normal Distribution
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	420
container_issue	2
container_start_page	419
container_title	Mayo Clinic proceedings
container_volume	97
creator	Al-Juhaishi, Taha Al-Kindi, Sadeer G
description
doi_str_mv	10.1016/j.mayocp.2021.11.029
format	Article
fullrecord	<record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2626009723</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A697577849</galeid><sourcerecordid>A697577849</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-62f06b48637f5f2ad910116c31895a6898b9e0ef3f4639fdd03115d599da25653</originalsourceid><addsrcrecordid>eNpVkcFO3DAQhi3UChbKG6Aqp6qXpGM7duIjrCggLeVQOFuOM168cuJtnID27Ru0gEBzGGn0_aMZfYScUSgoUPlrU3RmF-22YMBoQWkBTB2QBVUly4Uo5ReyAGAil1TJI3Kc0gYAKqXKQ3LEBWVQQbkgy7_T8OSfTMjufYeZ77Nr7MwYQ1x7m92a4Ne96a3HlN01uEvZH3y2sWvyC-xdHNpsZZ6_ka_OhISnr_2EPPy-vF9e56u7q5vl-Sq3vGJjLpkD2ZS15JUTjplWzX9QaTmtlTCyVnWjENBxV0quXNsCp1S0QqnWMCEFPyE_93u3Q_w3YRp155PFEEyPcUqaSSYBVMX4jBZ7dG0Caj-fOg7GztVi523s0fl5fi5VJaqqLtUc-PEh8IgmjI8phmn0sU-fwXIP2iGmNKDT28F3ZthpCvpFjN7ovRj9IkZTqmcxc-z76-1T02H7Hnozwf8DUr2Iqg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2626009723</pqid></control><display><type>article</type><title>Survival Time in Hematologic Malignancies Obeys Newcomb-Benford Law</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Al-Juhaishi, Taha ; Al-Kindi, Sadeer G</creator><creatorcontrib>Al-Juhaishi, Taha ; Al-Kindi, Sadeer G</creatorcontrib><identifier>ISSN: 0025-6196</identifier><identifier>EISSN: 1942-5546</identifier><identifier>DOI: 10.1016/j.mayocp.2021.11.029</identifier><identifier>PMID: 35120704</identifier><language>eng</language><publisher>England: Elsevier, Inc</publisher><subject>Databases, Factual ; Hematologic Neoplasms - mortality ; Hematologic Neoplasms - therapy ; Humans ; Models, Theoretical ; Normal Distribution</subject><ispartof>Mayo Clinic proceedings, 2022-02, Vol.97 (2), p.419-420</ispartof><rights>COPYRIGHT 2022 Elsevier, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c372t-62f06b48637f5f2ad910116c31895a6898b9e0ef3f4639fdd03115d599da25653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35120704$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Juhaishi, Taha</creatorcontrib><creatorcontrib>Al-Kindi, Sadeer G</creatorcontrib><title>Survival Time in Hematologic Malignancies Obeys Newcomb-Benford Law</title><title>Mayo Clinic proceedings</title><addtitle>Mayo Clin Proc</addtitle><subject>Databases, Factual</subject><subject>Hematologic Neoplasms - mortality</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Humans</subject><subject>Models, Theoretical</subject><subject>Normal Distribution</subject><issn>0025-6196</issn><issn>1942-5546</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkcFO3DAQhi3UChbKG6Aqp6qXpGM7duIjrCggLeVQOFuOM168cuJtnID27Ru0gEBzGGn0_aMZfYScUSgoUPlrU3RmF-22YMBoQWkBTB2QBVUly4Uo5ReyAGAil1TJI3Kc0gYAKqXKQ3LEBWVQQbkgy7_T8OSfTMjufYeZ77Nr7MwYQ1x7m92a4Ne96a3HlN01uEvZH3y2sWvyC-xdHNpsZZ6_ka_OhISnr_2EPPy-vF9e56u7q5vl-Sq3vGJjLpkD2ZS15JUTjplWzX9QaTmtlTCyVnWjENBxV0quXNsCp1S0QqnWMCEFPyE_93u3Q_w3YRp155PFEEyPcUqaSSYBVMX4jBZ7dG0Caj-fOg7GztVi523s0fl5fi5VJaqqLtUc-PEh8IgmjI8phmn0sU-fwXIP2iGmNKDT28F3ZthpCvpFjN7ovRj9IkZTqmcxc-z76-1T02H7Hnozwf8DUr2Iqg</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Al-Juhaishi, Taha</creator><creator>Al-Kindi, Sadeer G</creator><general>Elsevier, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202202</creationdate><title>Survival Time in Hematologic Malignancies Obeys Newcomb-Benford Law</title><author>Al-Juhaishi, Taha ; Al-Kindi, Sadeer G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-62f06b48637f5f2ad910116c31895a6898b9e0ef3f4639fdd03115d599da25653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Databases, Factual</topic><topic>Hematologic Neoplasms - mortality</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Humans</topic><topic>Models, Theoretical</topic><topic>Normal Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Juhaishi, Taha</creatorcontrib><creatorcontrib>Al-Kindi, Sadeer G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Mayo Clinic proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Juhaishi, Taha</au><au>Al-Kindi, Sadeer G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Time in Hematologic Malignancies Obeys Newcomb-Benford Law</atitle><jtitle>Mayo Clinic proceedings</jtitle><addtitle>Mayo Clin Proc</addtitle><date>2022-02</date><risdate>2022</risdate><volume>97</volume><issue>2</issue><spage>419</spage><epage>420</epage><pages>419-420</pages><issn>0025-6196</issn><eissn>1942-5546</eissn><cop>England</cop><pub>Elsevier, Inc</pub><pmid>35120704</pmid><doi>10.1016/j.mayocp.2021.11.029</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0025-6196
ispartof	Mayo Clinic proceedings, 2022-02, Vol.97 (2), p.419-420
issn	0025-6196 1942-5546
language	eng
recordid	cdi_proquest_miscellaneous_2626009723
source	MEDLINE; Alma/SFX Local Collection
subjects	Databases, Factual Hematologic Neoplasms - mortality Hematologic Neoplasms - therapy Humans Models, Theoretical Normal Distribution
title	Survival Time in Hematologic Malignancies Obeys Newcomb-Benford Law
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A43%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Time%20in%20Hematologic%20Malignancies%20Obeys%20Newcomb-Benford%20Law&rft.jtitle=Mayo%20Clinic%20proceedings&rft.au=Al-Juhaishi,%20Taha&rft.date=2022-02&rft.volume=97&rft.issue=2&rft.spage=419&rft.epage=420&rft.pages=419-420&rft.issn=0025-6196&rft.eissn=1942-5546&rft_id=info:doi/10.1016/j.mayocp.2021.11.029&rft_dat=%3Cgale_proqu%3EA697577849%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2626009723&rft_id=info:pmid/35120704&rft_galeid=A697577849&rfr_iscdi=true